Pharmaceutical

Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas.

Apr 23, 2024 - 00:00
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas.
Read the original article

Tags:

Previous Article

Lorcaserin hydrochloride by EpyGenix Therapeutics for Dravet Syndrome (Severe My...

Next Article

Datopotamab deruxtecan by Daiichi Sankyo for Head And Neck Squamous Cell Carcino...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA greenlights Regeneron’s Dupixent for the treatment of COPD

FDA greenlights Regeneron’s Dupixent for the treatment ...

Sep 28, 2024

Sterilisation Solutions, Equipment and Services for the Pharmaceutical Industry

Sterilisation Solutions, Equipment and Services for the...

Oct 2, 2024

STAT+: FDA has some safety concerns about CRISPR-based sickle cell treatment, documents show

STAT+: FDA has some safety concerns about CRISPR-based ...

Oct 28, 2023